Cardiovascular diseases
On February 22nd, our hearts go out to Hypertrophic Cardiomyopathy (HCM)
- Hypertrophic Cardiomyopathy is a common genetic disorder that affects the heart muscle.
- The disease affects people all over the world - regardless of gender, age or ethnicity.
- HCM is often hereditary or caused by a genetic mutation.
- 1 in 330 people is affected by a cardiomyopathy.
- It therefore represents a major burden for patients, families, the healthcare system and society.
- HCM receives little policy attention, and practitioners are generally not familiar with the diagnosis and treatment of the disease. Therefore, awareness of HCM is essential/of vital importance.
The report 'Cardiomyopathies Matter' provides policy recommendations to improve the detection and treatment of patients with cardiomyopathies in Europe.
Our dedicated HCM page provides more information about HCM, such as clinical picture, diagnosis and pathophysiology.
Important organizations
Harteraad
The organization helps people with cardiovascular diseases and their loved ones with practical, social and emotional support. Harteraad represents the interests of 1.5 million people with cardiovascular diseases.
Cardiomyopathy Research Netherlands
Cardiomyopathy Research Netherlands is a national foundation for patients with cardiomyopathy, their loved ones and healthcare professionals. Patients and physician-researchers are working together to find an answer and solution for the congenital and genetic heart muscle disorder cardiomyopathy.
BMS is leading in the development of groundbreaking therapies for the treatment of patients with cardiovascular diseases.
Cardiovascular diseases include all diseases that affect the cardiovascular system and the blood and lymphatic vessels, such as myocardial infarction, stroke and venous thromboembolism.
In the Netherlands, there are about 1.7 million people with a cardiovascular diseases.*
- 372,000 people live with the consequences of a cerebral hemorrhage or cerebral infarction.
- Every day, about 95 people are hospitalized with a heart attack.
Early detection of these diseases, treatment of risk factors and prevention are important to limit the impact of cardiovascular diseases. Current research at Bristol Myers Squibb is therefore focused on the development of therapies for stroke prevention and the treatment of venous thromboembolism. Stroke prevention focuses on atrial fibrillation, one of the major stroke risk factors.